Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anri Aki

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Plos One|June 29, 2017
Hypomorphic A20 expression confers susceptibility to psoriasisAnri Aki, Miyuki Nagasaki, Barbara Ann Malynn, et al.
Bioorganic & Medicinal Chemistry Letters|July 15, 2017
Discovery of DS79182026: A potent orally active hepcidin production inhibitorTakeshi Fukuda, Riki Goto, Toshihiro Kiho, et al.
Bioorganic & Medicinal Chemistry Letters|October 29, 2017
Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivativesTakeshi Fukuda, Riki Goto, Toshihiro Kiho, et al.
Bioorganic & Medicinal Chemistry Letters|September 16, 2018
Discovery of DS42450411 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4-aminopyrimidine derivativesTakeshi Fukuda, Takashi Ishiyama, Takahiro Katagiri, et al.
FASEB Bioadvances|August 22, 2020
Anti-ORAI1 antibody DS-2741a, a specific CRAC channel blocker, shows ideal therapeutic profiles for allergic disease via suppression of aberrant T-cell and mast cell activationAnri Aki, Kento Tanaka, Nobumi Nagaoka, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Plos One|June 29, 2017
Hypomorphic A20 expression confers susceptibility to psoriasisAnri Aki, Miyuki Nagasaki, Barbara Ann Malynn, et al.
Bioorganic & Medicinal Chemistry Letters|July 15, 2017
Discovery of DS79182026: A potent orally active hepcidin production inhibitorTakeshi Fukuda, Riki Goto, Toshihiro Kiho, et al.
Bioorganic & Medicinal Chemistry Letters|October 29, 2017
Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivativesTakeshi Fukuda, Riki Goto, Toshihiro Kiho, et al.
Bioorganic & Medicinal Chemistry Letters|September 16, 2018
Discovery of DS42450411 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4-aminopyrimidine derivativesTakeshi Fukuda, Takashi Ishiyama, Takahiro Katagiri, et al.
FASEB Bioadvances|August 22, 2020
Anti-ORAI1 antibody DS-2741a, a specific CRAC channel blocker, shows ideal therapeutic profiles for allergic disease via suppression of aberrant T-cell and mast cell activationAnri Aki, Kento Tanaka, Nobumi Nagaoka, et al.
Pageof 1